APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peptide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025194 pages

Choose your research edition.

Industry ResearchPeptide Vaccine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Vaccine Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Peptide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Vaccine Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Vaccine Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Peptide Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide Vaccine include Anergis, Antigen Express, Apitope Technology, Artificial Cell Technologies, Benovus Bio, Celgene Corporation, Immatics biotechnologies, ImmunoCellular Therapeutics and ISA Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Vaccine Segment by Company

Anergis

Antigen Express

Apitope Technology

Artificial Cell Technologies

Benovus Bio

Celgene Corporation

Immatics biotechnologies

ImmunoCellular Therapeutics

ISA Pharmaceuticals

Lytix Biopharma

OncoTherapy Science

Peptech

Pharmasyntez

Spotlight Innovation

Sumitomo Dainippon Pharma

TapImmune

Targovax

Merck

Peptide Vaccine Segment by Type

Solution Phase Synthesis (SPS)

Solid Phase Peptide Synthesis (SPPS)

Peptide Vaccine Segment by Application

Pancreatic Cancer

Gastric Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Others

Peptide Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Peptide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Peptide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Peptide Vaccine Industry Trends Table 2. Peptide Vaccine Industry Drivers Table 3. Peptide Vaccine Industry Opportunities and Challenges Table 4. Peptide Vaccine Industry Restraints Table 5. Global Peptide Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Peptide Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Peptide Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Peptide Vaccine Sales Market Share by Manufacturers Table 9. Global Peptide Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Peptide Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Peptide Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Peptide Vaccine Manufacturers, Product Type & Application Table 13. Global Peptide Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Solution Phase Synthesis (SPS) Table 17. Major Manufacturers of Solid Phase Peptide Synthesis (SPPS) Table 18. Global Peptide Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Peptide Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global Peptide Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global Peptide Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Peptide Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Peptide Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Peptide Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global Peptide Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global Peptide Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Peptide Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Pancreatic Cancer Table 29. Major Manufacturers of Gastric Cancer Table 30. Major Manufacturers of Breast Cancer Table 31. Major Manufacturers of Prostate Cancer Table 32. Major Manufacturers of Lung Cancer Table 33. Major Manufacturers of Others Table 34. Global Peptide Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Peptide Vaccine Sales by Application (2021-2026) & (K Units) Table 36. Global Peptide Vaccine Sales by Application (2027-2032) & (K Units) Table 37. Global Peptide Vaccine Sales Market Share by Application (2021-2026) Table 38. Global Peptide Vaccine Sales Market Share by Application (2027-2032) Table 39. Global Peptide Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Peptide Vaccine Revenue by Application (2021-2026) & (K Units) Table 41. Global Peptide Vaccine Revenue by Application (2027-2032) & (K Units) Table 42. Global Peptide Vaccine Revenue Market Share by Application (2021-2026) Table 43. Global Peptide Vaccine Revenue Market Share by Application (2027-2032) Table 44. Global Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Peptide Vaccine Sales by Region (2021-2026) & (K Units) Table 46. Global Peptide Vaccine Sales Market Share by Region (2021-2026) Table 47. Global Peptide Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Peptide Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 51. North America Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 52. Europe Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 54. Europe Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 61. Global Peptide Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Peptide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Peptide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Peptide Vaccine Revenue Market Share by Region (2021-2026) Table 65. Global Peptide Vaccine Revenue Market Share by Region (2027-2032) Table 66. Anergis Company Information Table 67. Anergis Business Overview Table 68. Anergis Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Anergis Peptide Vaccine Product Portfolio Table 70. Anergis Recent Development Table 71. Antigen Express Company Information Table 72. Antigen Express Business Overview Table 73. Antigen Express Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Antigen Express Peptide Vaccine Product Portfolio Table 75. Antigen Express Recent Development Table 76. Apitope Technology Company Information Table 77. Apitope Technology Business Overview Table 78. Apitope Technology Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Apitope Technology Peptide Vaccine Product Portfolio Table 80. Apitope Technology Recent Development Table 81. Artificial Cell Technologies Company Information Table 82. Artificial Cell Technologies Business Overview Table 83. Artificial Cell Technologies Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Artificial Cell Technologies Peptide Vaccine Product Portfolio Table 85. Artificial Cell Technologies Recent Development Table 86. Benovus Bio Company Information Table 87. Benovus Bio Business Overview Table 88. Benovus Bio Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Benovus Bio Peptide Vaccine Product Portfolio Table 90. Benovus Bio Recent Development Table 91. Celgene Corporation Company Information Table 92. Celgene Corporation Business Overview Table 93. Celgene Corporation Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Celgene Corporation Peptide Vaccine Product Portfolio Table 95. Celgene Corporation Recent Development Table 96. Immatics biotechnologies Company Information Table 97. Immatics biotechnologies Business Overview Table 98. Immatics biotechnologies Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Immatics biotechnologies Peptide Vaccine Product Portfolio Table 100. Immatics biotechnologies Recent Development Table 101. ImmunoCellular Therapeutics Company Information Table 102. ImmunoCellular Therapeutics Business Overview Table 103. ImmunoCellular Therapeutics Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. ImmunoCellular Therapeutics Peptide Vaccine Product Portfolio Table 105. ImmunoCellular Therapeutics Recent Development Table 106. ISA Pharmaceuticals Company Information Table 107. ISA Pharmaceuticals Business Overview Table 108. ISA Pharmaceuticals Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. ISA Pharmaceuticals Peptide Vaccine Product Portfolio Table 110. ISA Pharmaceuticals Recent Development Table 111. Lytix Biopharma Company Information Table 112. Lytix Biopharma Business Overview Table 113. Lytix Biopharma Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Lytix Biopharma Peptide Vaccine Product Portfolio Table 115. Lytix Biopharma Recent Development Table 116. OncoTherapy Science Company Information Table 117. OncoTherapy Science Business Overview Table 118. OncoTherapy Science Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. OncoTherapy Science Peptide Vaccine Product Portfolio Table 120. OncoTherapy Science Recent Development Table 121. Peptech Company Information Table 122. Peptech Business Overview Table 123. Peptech Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Peptech Peptide Vaccine Product Portfolio Table 125. Peptech Recent Development Table 126. Pharmasyntez Company Information Table 127. Pharmasyntez Business Overview Table 128. Pharmasyntez Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Pharmasyntez Peptide Vaccine Product Portfolio Table 130. Pharmasyntez Recent Development Table 131. Spotlight Innovation Company Information Table 132. Spotlight Innovation Business Overview Table 133. Spotlight Innovation Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Spotlight Innovation Peptide Vaccine Product Portfolio Table 135. Spotlight Innovation Recent Development Table 136. Sumitomo Dainippon Pharma Company Information Table 137. Sumitomo Dainippon Pharma Business Overview Table 138. Sumitomo Dainippon Pharma Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Sumitomo Dainippon Pharma Peptide Vaccine Product Portfolio Table 140. Sumitomo Dainippon Pharma Recent Development Table 141. TapImmune Company Information Table 142. TapImmune Business Overview Table 143. TapImmune Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. TapImmune Peptide Vaccine Product Portfolio Table 145. TapImmune Recent Development Table 146. Targovax Company Information Table 147. Targovax Business Overview Table 148. Targovax Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Targovax Peptide Vaccine Product Portfolio Table 150. Targovax Recent Development Table 151. Merck Company Information Table 152. Merck Business Overview Table 153. Merck Peptide Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Merck Peptide Vaccine Product Portfolio Table 155. Merck Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Peptide Vaccine Distributors List Table 159. Peptide Vaccine Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Peptide Vaccine Product Image Figure 2. Global Peptide Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Peptide Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Peptide Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Solution Phase Synthesis (SPS) Image Figure 9. Solid Phase Peptide Synthesis (SPPS) Image Figure 10. Global Peptide Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Peptide Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Peptide Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Peptide Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Peptide Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Peptide Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Pancreatic Cancer Image Figure 17. Gastric Cancer Image Figure 18. Breast Cancer Image Figure 19. Prostate Cancer Image Figure 20. Lung Cancer Image Figure 21. Others Image Figure 22. Global Peptide Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Peptide Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Peptide Vaccine Sales Market Share by Application (2021-2032) Figure 25. Global Peptide Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Peptide Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Peptide Vaccine Revenue Market Share by Application (2021-2032) Figure 28. North America Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 30. U.S. Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 35. Germany Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 42. China Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 50. Brazil Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Peptide Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Peptide Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Peptide Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Peptide Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. North America Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Peptide Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Europe Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Peptide Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Peptide Vaccine Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Peptide Vaccine Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Peptide Vaccine Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Solution Phase Synthesis (SPS)
  • Solid Phase Peptide Synthesis (SPPS)
Applications
  • Pancreatic Cancer
  • Gastric Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Others
Companies covered
  • Anergis
  • Antigen Express
  • Apitope Technology
  • Artificial Cell Technologies
  • Benovus Bio
  • Celgene Corporation
  • Immatics biotechnologies
  • ImmunoCellular Therapeutics
  • ISA Pharmaceuticals
  • Lytix Biopharma
  • OncoTherapy Science
  • Peptech
  • Pharmasyntez
  • Spotlight Innovation
  • Sumitomo Dainippon Pharma
  • TapImmune
  • Targovax
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Peptide Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Peptide Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Peptide Vaccine Market Dynamics
  1. 2.1 Peptide Vaccine Industry Trends
  2. 2.2 Peptide Vaccine Industry Drivers
  3. 2.3 Peptide Vaccine Industry Opportunities and Challenges
  4. 2.4 Peptide Vaccine Industry Restraints
3 Peptide Vaccine Market by Manufacturers
  1. 3.1 Global Peptide Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Peptide Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Peptide Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Peptide Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Peptide Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Peptide Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide Vaccine Tier 1, Tier 2, and Tier 3
4 Peptide Vaccine Market by Type
  1. 4.1 Peptide Vaccine Type Introduction
  2. 4.1.1 Solution Phase Synthesis (SPS)
  3. 4.1.2 Solid Phase Peptide Synthesis (SPPS)
  4. 4.2 Global Peptide Vaccine Sales by Type
  5. 4.2.1 Global Peptide Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peptide Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Peptide Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Peptide Vaccine Revenue by Type
  9. 4.3.1 Global Peptide Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peptide Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Peptide Vaccine Revenue Market Share by Type (2021-2032)
5 Peptide Vaccine Market by Application
  1. 5.1 Peptide Vaccine Application Introduction
  2. 5.1.1 Pancreatic Cancer
  3. 5.1.2 Gastric Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 Lung Cancer
  7. 5.1.6 Others
  8. 5.2 Global Peptide Vaccine Sales by Application
  9. 5.2.1 Global Peptide Vaccine Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Peptide Vaccine Sales by Application (2021-2032)
  11. 5.2.3 Global Peptide Vaccine Sales Market Share by Application (2021-2032)
  12. 5.3 Global Peptide Vaccine Revenue by Application
  13. 5.3.1 Global Peptide Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Peptide Vaccine Revenue by Application (2021-2032)
  15. 5.3.3 Global Peptide Vaccine Revenue Market Share by Application (2021-2032)
6 Global Peptide Vaccine Sales by Region
  1. 6.1 Global Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Peptide Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Peptide Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Peptide Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Peptide Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Peptide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Peptide Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Peptide Vaccine Revenue by Region
  1. 7.1 Global Peptide Vaccine Revenue by Region
  2. 7.1.1 Global Peptide Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Peptide Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Peptide Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Peptide Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Peptide Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Peptide Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Peptide Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Peptide Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Peptide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Anergis
  2. 8.1.1 Anergis Company Information
  3. 8.1.2 Anergis Business Overview
  4. 8.1.3 Anergis Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Anergis Peptide Vaccine Product Portfolio
  6. 8.1.5 Anergis Recent Developments
  7. 8.2 Antigen Express
  8. 8.2.1 Antigen Express Company Information
  9. 8.2.2 Antigen Express Business Overview
  10. 8.2.3 Antigen Express Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Antigen Express Peptide Vaccine Product Portfolio
  12. 8.2.5 Antigen Express Recent Developments
  13. 8.3 Apitope Technology
  14. 8.3.1 Apitope Technology Company Information
  15. 8.3.2 Apitope Technology Business Overview
  16. 8.3.3 Apitope Technology Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Apitope Technology Peptide Vaccine Product Portfolio
  18. 8.3.5 Apitope Technology Recent Developments
  19. 8.4 Artificial Cell Technologies
  20. 8.4.1 Artificial Cell Technologies Company Information
  21. 8.4.2 Artificial Cell Technologies Business Overview
  22. 8.4.3 Artificial Cell Technologies Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Artificial Cell Technologies Peptide Vaccine Product Portfolio
  24. 8.4.5 Artificial Cell Technologies Recent Developments
  25. 8.5 Benovus Bio
  26. 8.5.1 Benovus Bio Company Information
  27. 8.5.2 Benovus Bio Business Overview
  28. 8.5.3 Benovus Bio Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Benovus Bio Peptide Vaccine Product Portfolio
  30. 8.5.5 Benovus Bio Recent Developments
  31. 8.6 Celgene Corporation
  32. 8.6.1 Celgene Corporation Company Information
  33. 8.6.2 Celgene Corporation Business Overview
  34. 8.6.3 Celgene Corporation Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Celgene Corporation Peptide Vaccine Product Portfolio
  36. 8.6.5 Celgene Corporation Recent Developments
  37. 8.7 Immatics biotechnologies
  38. 8.7.1 Immatics biotechnologies Company Information
  39. 8.7.2 Immatics biotechnologies Business Overview
  40. 8.7.3 Immatics biotechnologies Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Immatics biotechnologies Peptide Vaccine Product Portfolio
  42. 8.7.5 Immatics biotechnologies Recent Developments
  43. 8.8 ImmunoCellular Therapeutics
  44. 8.8.1 ImmunoCellular Therapeutics Company Information
  45. 8.8.2 ImmunoCellular Therapeutics Business Overview
  46. 8.8.3 ImmunoCellular Therapeutics Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ImmunoCellular Therapeutics Peptide Vaccine Product Portfolio
  48. 8.8.5 ImmunoCellular Therapeutics Recent Developments
  49. 8.9 ISA Pharmaceuticals
  50. 8.9.1 ISA Pharmaceuticals Company Information
  51. 8.9.2 ISA Pharmaceuticals Business Overview
  52. 8.9.3 ISA Pharmaceuticals Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ISA Pharmaceuticals Peptide Vaccine Product Portfolio
  54. 8.9.5 ISA Pharmaceuticals Recent Developments
  55. 8.10 Lytix Biopharma
  56. 8.10.1 Lytix Biopharma Company Information
  57. 8.10.2 Lytix Biopharma Business Overview
  58. 8.10.3 Lytix Biopharma Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lytix Biopharma Peptide Vaccine Product Portfolio
  60. 8.10.5 Lytix Biopharma Recent Developments
  61. 8.11 OncoTherapy Science
  62. 8.11.1 OncoTherapy Science Company Information
  63. 8.11.2 OncoTherapy Science Business Overview
  64. 8.11.3 OncoTherapy Science Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 OncoTherapy Science Peptide Vaccine Product Portfolio
  66. 8.11.5 OncoTherapy Science Recent Developments
  67. 8.12 Peptech
  68. 8.12.1 Peptech Company Information
  69. 8.12.2 Peptech Business Overview
  70. 8.12.3 Peptech Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Peptech Peptide Vaccine Product Portfolio
  72. 8.12.5 Peptech Recent Developments
  73. 8.13 Pharmasyntez
  74. 8.13.1 Pharmasyntez Company Information
  75. 8.13.2 Pharmasyntez Business Overview
  76. 8.13.3 Pharmasyntez Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pharmasyntez Peptide Vaccine Product Portfolio
  78. 8.13.5 Pharmasyntez Recent Developments
  79. 8.14 Spotlight Innovation
  80. 8.14.1 Spotlight Innovation Company Information
  81. 8.14.2 Spotlight Innovation Business Overview
  82. 8.14.3 Spotlight Innovation Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Spotlight Innovation Peptide Vaccine Product Portfolio
  84. 8.14.5 Spotlight Innovation Recent Developments
  85. 8.15 Sumitomo Dainippon Pharma
  86. 8.15.1 Sumitomo Dainippon Pharma Company Information
  87. 8.15.2 Sumitomo Dainippon Pharma Business Overview
  88. 8.15.3 Sumitomo Dainippon Pharma Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sumitomo Dainippon Pharma Peptide Vaccine Product Portfolio
  90. 8.15.5 Sumitomo Dainippon Pharma Recent Developments
  91. 8.16 TapImmune
  92. 8.16.1 TapImmune Company Information
  93. 8.16.2 TapImmune Business Overview
  94. 8.16.3 TapImmune Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 TapImmune Peptide Vaccine Product Portfolio
  96. 8.16.5 TapImmune Recent Developments
  97. 8.17 Targovax
  98. 8.17.1 Targovax Company Information
  99. 8.17.2 Targovax Business Overview
  100. 8.17.3 Targovax Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Targovax Peptide Vaccine Product Portfolio
  102. 8.17.5 Targovax Recent Developments
  103. 8.18 Merck
  104. 8.18.1 Merck Company Information
  105. 8.18.2 Merck Business Overview
  106. 8.18.3 Merck Peptide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Merck Peptide Vaccine Product Portfolio
  108. 8.18.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Vaccine Value Chain Analysis
  2. 9.1.1 Peptide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Vaccine Production Mode & Process
  6. 9.2 Peptide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Vaccine Distributors
  9. 9.2.3 Peptide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst